Topic Hubs
Each hub anchors a major topic in mass tort intelligence with a 150-word definition, related litigation tracks, glossary references, and external authoritative sources.
/topics/mass-tort
A mass tort is a civil action in which a large number of plaintiffs assert claims against one or a few corporate defendants for harm caused by a shared product, drug, device, or environmental exposure. Unlike class actions, each plaintiff retains an individual case with individual damages, but discovery, expert testimony, and pretrial rulings are typically consolidated through Multidistrict Litigation (MDL) in federal court or through a Judicial Council Coordination Proceeding (JCCP) in state court. Mass torts most commonly arise around pharmaceuticals, medical devices, environmental contaminants, and consumer products. Resolution usually occurs through bellwether trials that establish settlement valuations across the inventory, followed by a global settlement or matrix-based payout fund. Plaintiff law firms compete on intake velocity, science investment, and steering committee positioning during the early and middle stages of a mass tort.
10 torts · 7 glossary terms
/topics/mdl
Multidistrict Litigation (MDL) is a federal pretrial consolidation procedure created by 28 U.S.C. § 1407 and administered by the United States Judicial Panel on Multidistrict Litigation (JPML). When civil actions involving common questions of fact are pending in different federal districts, the JPML may transfer them to a single transferee judge for coordinated or consolidated pretrial proceedings. The transferee court handles discovery, dispositive motions, Daubert challenges, and bellwether trials. Cases that are not resolved at the MDL level are remanded to their originating district for trial. MDLs now account for over half of all pending federal civil cases. The MDL structure is the dominant procedural vehicle for pharmaceutical, medical device, and environmental mass torts and is the primary lens through which TortSignal scores litigation momentum.
7 torts · 6 glossary terms
/topics/glp-1
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injectable medications—including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and Trulicity—originally approved for type 2 diabetes and increasingly prescribed off-label for weight loss. Litigation alleges that manufacturers Novo Nordisk and Eli Lilly failed to warn patients about severe gastrointestinal adverse events including gastroparesis, intestinal pseudo-obstruction, ileus, and cyclic vomiting syndrome, as well as gallbladder disease, pancreatitis, and a rare optic-nerve condition called NAION. The class has tens of millions of U.S. users, and MDL 3094 in the Eastern District of Pennsylvania consolidates federal cases. Bellwether selection is underway. Science continues to evolve, with FDA label updates throughout 2024–2026 and additional adverse-event signals emerging in peer-reviewed literature.
1 torts · 3 glossary terms
/topics/pfas
Per- and polyfluoroalkyl substances (PFAS) are a family of more than 12,000 synthetic chemicals used since the 1940s in nonstick coatings, stain repellents, food packaging, and firefighting foams. Because the carbon-fluorine bond does not break down in the environment or human body, PFAS are commonly called "forever chemicals." Mounting epidemiological evidence links PFAS exposure—particularly to PFOA and PFOS—to kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and pregnancy-induced hypertension. The largest litigation tracks are MDL 2873 (Aqueous Film-Forming Foam personal injury and municipal water) and a growing wave of state attorney general actions against 3M, DuPont, Chemours, and other manufacturers. The EPA finalized PFOA and PFOS designations as hazardous substances under CERCLA in 2024, dramatically increasing cleanup liability and discovery exposure.
2 torts · 4 glossary terms
/topics/bellwether
Bellwether trials are a small number of representative cases tried early within an MDL or coordinated proceeding to test legal theories, expert testimony, and damages models. The verdicts and rulings from bellwethers do not bind the remaining inventory but they create powerful settlement leverage by signaling the likely value and outcome distribution across thousands of similar claims. Bellwether case selection typically follows a multi-step Lone Pine-style screening process, plaintiff and defense picks, and randomized stratification by injury severity, geography, and exposure profile. Bellwether outcomes are the single strongest predictor of global settlement timing and valuation, which is why TortSignal weights bellwether proximity heavily in its momentum scoring algorithm. Attorneys who position cases for inclusion in early bellwether pools often capture significantly higher per-case recovery.
5 torts · 4 glossary terms
/topics/plaintiff-litigation
Plaintiff litigation strategy in mass torts is the discipline of identifying emerging product liability or environmental exposure claims, building scientific and regulatory foundations, organizing leadership through Plaintiff Steering Committees, financing case acquisition and bellwether work, and ultimately negotiating settlement matrices or trying cases to verdict. Successful plaintiff strategies combine early-stage science investment, aggressive but qualified intake, geographic targeting in plaintiff-favorable jurisdictions, and disciplined case workup. Because mass torts follow predictable lifecycle curves—from emerging signal, to MDL formation, to bellwether trials, to global resolution—firms that move at the right stage capture outsized economics. TortSignal exists to give plaintiff firms a real-time view of where each litigation sits on that curve and how competitive the intake market currently is for each tort.
8 torts · 6 glossary terms
/topics/fda-enforcement
FDA enforcement actions—warning letters, label changes, boxed warnings, post-market study orders, and product recalls—are leading indicators of product liability litigation. When the FDA requires a manufacturer to update labeling for newly recognized adverse events, plaintiff attorneys frequently file suit alleging the manufacturer knew or should have known about the risk earlier. The FDA Adverse Event Reporting System (FAERS), Drug Safety Communications, and the MedWatch program generate publicly observable signals that precede mass tort formation by 12 to 36 months. TortSignal monitors FDA enforcement output continuously across drug classes most likely to produce mass tort liability and folds those signals into the science-strength component of each tort's composite score. Recent examples include GLP-1 agonist label updates, Tylenol acetaminophen warnings, and Depo-Provera meningioma additions.
3 torts · 2 glossary terms
/topics/drug-injury
Drug injury litigation is a subset of mass tort practice focused on prescription pharmaceuticals and over-the-counter medications. Claims typically allege design defect, manufacturing defect, failure to warn, negligent misrepresentation, breach of express or implied warranty, and—under state consumer protection statutes—deceptive marketing. Federal preemption doctrine, particularly under Wyeth v. Levine and PLIVA v. Mensing, controls when state-law claims survive against branded versus generic manufacturers. Successful drug injury cases require strong general causation epidemiology, plausible specific causation in individual plaintiffs, and a documented warning gap between what the manufacturer knew and what physicians were told. TortSignal tracks the pharmaceutical pipeline of emerging drug injury claims, scoring each based on FDA signal strength, scientific publication velocity, and MDL formation likelihood.
4 torts · 5 glossary terms